Generally There are more retail investors and not enough dealer chips. But Hongri Pharmaceuticals is also considered a low valuation pharmaceutical technology dark horse stock. The reasons are as follows:
1. High-tech biomedical industry advantage. The company has traditional Chinese medicine, chemical medicine, high-end medical equipment, three high-tech areas of core science and technology, in the country's major fierce home focus on the development of emerging industries. National 13th Five-Year Plan intends to 3.6 trillion yuan industry output value growth to 8 trillion yuan. This year, the World Association of Traditional Chinese Medicine, accompanied by the President of the branch in China, will promote the globalization of traditional Chinese medicine, ushering in a new opportunity for the development of traditional Chinese medicine.
2. The company's fundamentals have been reversed. At present, it has developed into a high-tech pharmaceutical and health industry cluster spanning modern Chinese medicine, chemical medicine, biotechnology medicine, pharmaceutical excipients and APIs, medical devices, medical and health services and many other fields, integrating investment and financing, research and development, production and sales. The company completed a major reorganization, the company's reorganization has always been the stock to produce large fluctuations in the rise of the subject, but not only did not go up instead of lagging, there may be a delayed reaction. Since this year the company announced a number of new drugs for the treatment of coronary heart disease, its scientific and technological content, high value-added, widely used. Cardiovascular disease is currently the main killer of human death and health, cardiovascular disease and cancer is the cause of human death of the champion and runner-up, its mortality rate accounted for about 40%, 36% or so. The company produces a variety of drugs for the treatment of cardiovascular disease, the prospect is unlimited.